NQO1 and hepatocellular carcinoma: Concomitant high NQO1 and low CAT mRNA levels (high NQO1:CAT ratios (Figure 2C, p < 0.0001) in HCC tumor tissue offer an ideal target for NQO1 bioactivatable drugs.